Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 first-in-human, randomized, double-blind, placebo-controlled, dose escalation trial evaluating the safety, tolerability, and pharmacokinetics of PanFlu candidate CR9114 through intranasal administration in healthy volunteers

Next Previous
Search
Trial Profile

Phase 1 first-in-human, randomized, double-blind, placebo-controlled, dose escalation trial evaluating the safety, tolerability, and pharmacokinetics of PanFlu candidate CR9114 through intranasal administration in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CR 9114 (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 25 Apr 2023 New trial record
    • 19 Apr 2023 According to Leyden Laboratories B.V., media release, the company announced the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114; Trial data are expected later this year, after which Leyden Labs plans to initiate subsequent Phase 2 studies of this PanFlu candidate.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top